TGA approval for Neurotech

Latest News

Neurotech (ASX:NTI) has received confirmation from the TGA its Mente Autism has been included on the Australian Register of Therapeutic Goods (ARTG).

The company said its inclusion on the ARTG marks a significant milestone, enabling it to distribute and sell Mente Autism in Australia. Mente Autism is registered as a biofeedback system in the category Medical Device Class IIa.

Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

Selection of a distribution partner for Mente Autism in Australia is underway and expected to be finalised in third quarter 2017.

According to Wolfgang Storf, CEO of Neurotech, “This is another major milestone for our company. Inclusion on the ARTG enables us to legally supply Mente Autism in Australia and gives us access to a very large market with enormous potential. In line with our vision to improve the lives of people with neurological conditions, we can now help the many Australian families with children who are diagnosed with Autism Spectrum Disorder (ASD). These are exciting times for Neurotech and Mente Autism.”

Neurotech also confirmed it will be attending the 15th German Autism Congress to be held in Germany later this week. The company will use the event to launch Mente Autism in the key market of Germany.